NASDAQ: NVAXNovavax Inc Stock
$6.94-0.21 (-2.94%)
Updated Jun 13, 2025
NVAX Price
$6.94
Fair Value Price
N/A
Market Cap
$1.12B
52 Week Low
$5.01
52 Week High
$17.81
P/E
2.29x
P/B
-14.86x
P/S
0.82x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.25B
Earnings
$478.70M
Gross Margin
87.4%
Operating Margin
40.66%
Profit Margin
38.1%
Debt to Equity
-18.09
Operating Cash Flow
-$189M
Beta
1.63
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NVAX Overview
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NVAX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NVAX
Ranked#53 of 464
Ranked#53 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important NVAX news, forecast changes, insider trades & much more!
NVAX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NVAX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NVAX is good value based on its earnings relative to its share price (2.29x), compared to the US market average (31.36x)
P/E vs Market Valuation
NVAX is good value based on its earnings relative to its share price (2.29x), compared to the US Biotechnology industry average (-108.97x)
P/E vs Industry Valuation
NVAX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more NVAX due diligence checks available for Premium users.
Valuation
NVAX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
2.29x
Industry
-108.97x
Market
31.36x
NVAX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
NVAX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
NVAX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-14.86x
Industry
4.66x
NVAX's financial health
Profit margin
Revenue
$666.7M
Net Income
$518.6M
Profit Margin
77.8%
NVAX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
NVAX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.3B
Liabilities
$1.4B
Debt to equity
-18.09
NVAX's short-term assets ($868.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NVAX's long-term liabilities ($946.47M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NVAX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NVAX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$185.5M
Investing
-$73.3M
Financing
-$7.1M
NVAX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NVAX vs Biotech Stocks
Novavax Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.